GTCDxᵀᴹ Monkey Anti-AAV8 Antibody ELISA Kit

Name: GTCDxᵀᴹ Monkey Anti-AAV8 Antibody ELISA Kit
SKU: DEIASL345Y
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum

Species Reactivity

Monkey

Detection Method

iELISA

Intended Use

The Anti-AAV8 ELISA is used as an analytical tool for qualitative determination of antibodies to AAV8 in serum.

Contents of Kit

No.	Components	Size	Storage Conditions
1	AAV8 Capsid Coated Microtiter Plate	12×8 wells	2-8°C
2	Negative Control, ready to use	1 × 1 mL	2-8°C
3	Anti-AAV8 Positive Control, ready to use	1 × 1 mL	2-8°C
4	Anti-IgG Conjugate, 100×	1 × 0.12 mL	2-8°C
5	Sample Diluent, ready to use	1 × 50 mL	2-8°C
6	Wash Buffer, 20 ×	1 × 50 mL	2-8°C
7	TMB Substrate, ready to use	2 × 6 mL	2-8°C
8	Stop Solution, ready to use	1 × 7 mL	2-8°C
9	Instruction Manual	1

Storage

1. All reagents should be stored at 2°C to 8°C for stability.
2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
3. Before using, bring all components to room temperature (18-25°C). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

General Description

Researchers have used AAV-based vectors in pre-clinical research and in clinical trials in which AAV-based vectors have demonstrated a good safety profile. AAVs have also demonstrated lasting therapeutic gene expression following a single treatment in preclinical and clinical studies.
AAV serotype 8 (AAV8) shows a significantly greater liver transduction efficiency than those of other serotypes, which has resulted in efforts to develop this virus as a gene therapy vector for hemophilia A and familial hypercholesterolemia.
One of the major challenges in AAV-based gene therapy is the presence of circulating anti-AAV neutralizing antibodies, which can pre-exist in patients and may prevent successful gene transfer. High levels of circulating anti-AAV neutralizing antibodies can develop after a single administration of gene therapy and can prevent successful gene transfer in patients.

Citations